Vicore Pharma Holding AB (SE:VICO)
:VICO
Want to see SE:VICO full AI Analyst Report?
VICO Stock Chart & Stats
kr11.08
-kr0.08(-1.06%)
At close: 4:00 PM EST
kr11.08
-kr0.08(-1.06%)
Day’s Range― - ―
52-Week Rangekr7.35 - kr14.10
Previous CloseN/A
Volume158.42K
Average Volume (3M)520.11K
Market Cap
kr3.10B
Enterprise Valuekr2.22B
Total Cash (Recent Filing)kr1.06B
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.59
Next Earnings
Aug 21, 2026EPS Estimate
-0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.42
Shares Outstanding281,525,600
10 Day Avg. Volume692,423
30 Day Avg. Volume520,111
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)2.47
Price to Sales (P/S)710.16
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr38.00Price Target Upside242.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.81
Revenue Forecast (FY)kr8.09M
Bulls Say, Bears Say
Bulls Say
Low LeverageAn essentially zero-debt balance sheet is a durable strength for a clinical-stage biotech. It reduces refinancing risk and preserves strategic optionality to fund trials, pursue partnerships or structure non-dilutive deals, supporting program advancement over months.
Focused PipelineA concentrated R&D focus on AT2R-targeting small molecules for severe lung disease (IPF) creates clear scientific differentiation and program clarity. This niche focus can facilitate specialized partnerships, streamlined trial design and regulatory engagement over the medium term.
Expanded Equity BaseMaterial equity expansion provides a funding cushion and strengthens the balance sheet, enabling continued preclinical/clinical investment without immediate debt issuance. This supports durable R&D spending capacity while management pursues clinical milestones or collaboration deals.
Bears Say
Persistent Cash BurnConsistent and worsening negative operating cash flow signals a structural funding gap. For a clinical-stage developer this erodes runway, creates recurring dilution risk, and limits capacity to progress multiple programs simultaneously without external financing or partner funding.
Revenue VolatilityLarge year-to-year revenue swings and a steep 2025 decline indicate reliance on episodic milestone or one-off receipts rather than recurring income. This instability complicates multi-year planning, increases dependence on capital markets, and weakens the firm's ability to sustain operations through trials.
Deep Operating LossesSubstantial and growing operating losses imply negative returns on invested capital and prolonged inability to self-fund. Persistent losses will pressure the balance sheet over time, heighten dilution or financing demands, and constrain strategic options absent clinical success or new funding sources.
Vicore Pharma Holding AB News
VICO FAQ
What was Vicore Pharma Holding AB’s price range in the past 12 months?
Vicore Pharma Holding AB lowest stock price was kr7.35 and its highest was kr14.10 in the past 12 months.
What is Vicore Pharma Holding AB’s market cap?
Vicore Pharma Holding AB’s market cap is kr3.10B.
When is Vicore Pharma Holding AB’s upcoming earnings report date?
Vicore Pharma Holding AB’s upcoming earnings report date is Aug 21, 2026 which is in 91 days.
How were Vicore Pharma Holding AB’s earnings last quarter?
Vicore Pharma Holding AB released its earnings results on May 06, 2026. The company reported -kr0.39 earnings per share for the quarter, beating the consensus estimate of -kr0.48 by kr0.09.
Is Vicore Pharma Holding AB overvalued?
According to Wall Street analysts Vicore Pharma Holding AB’s price is currently Undervalued.
Does Vicore Pharma Holding AB pay dividends?
Vicore Pharma Holding AB does not currently pay dividends.
What is Vicore Pharma Holding AB’s EPS estimate?
Vicore Pharma Holding AB’s EPS estimate is -0.45.
How many shares outstanding does Vicore Pharma Holding AB have?
Vicore Pharma Holding AB has 281,525,600 shares outstanding.
What happened to Vicore Pharma Holding AB’s price movement after its last earnings report?
Vicore Pharma Holding AB reported an EPS of -kr0.39 in its last earnings report, beating expectations of -kr0.48. Following the earnings report the stock price went up 6.557%.
Which hedge fund is a major shareholder of Vicore Pharma Holding AB?
Currently, no hedge funds are holding shares in SE:VICO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vicore Pharma Holding AB
Vicore Pharma Holding AB (publ) engages in the research and development of pharmaceutical products for the treatments for rare lung diseases. The company is developing VP01, a small molecule compound for oral administration that is in phase II clinical trial for the treatment of interstitial lung diseases, idiopathic pulmonary fibrosis (IPF), systemic sclerosis, and COVID-19; and VP02, a formulation and delivery route for an existing immunomodulatory compound, which is preclinical trials to treat patients with IPF. It has a cooperation and development agreement with Emeriti Bio AB; license agreement with Nanologica AB (publ); and a collaboration agreement with Alex Therapeutics AB for the development and clinical validation of a digital therapeutic (DTx) built on the Alex DTx platform. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Gothenburg, Sweden.
VICO Stock 12 Month Forecast
Average Price Target
kr38.00
▲(242.96% Upside)
Technical Analysis
Hansa Biopharma AB
―
BioInvent International AB
―
SynAct Pharma AB
―
Xspray Pharma AB
―
Cantargia AB
―
Options Prices
Currently, No data available
---